Axsome Therapeutics gets FDA support to submit sNDA for its Alzheimer’s disease agitation treatment
Axsome Therapeutics (NASDAQ:AXSM) said on Monday that in the FDA meeting minutes, the agency has supported a supplemental NDA ...
KERA News53m
Alzheimer's organizations laud bill to create Texas dementia research institute
Texas Senate Bill 5 would create the Dementia Prevention and Research Institute of Texas. Voters would be asked this fall to ...
BMJ19m
Lecanemab: European drug agency upholds decision to recommend Alzheimer’s drug
The European Medicines Association (EMA) has upheld its decision to recommend the Alzheimer’s drug lecanemab despite concerns that any clinical benefits are small and there is a risk of brain swelling ...
As baby boomers turn 80, there aren't enough doctors to treat 'emergency levels' of dementia patients
The lifetime risk of dementia after age 55 is about 42%, according to a recent study published in the journal Nature Medicine. Around 1 million adults in the U.S. are projected to develop dementia ...
Hosted on MSN18m
LGVN Well Positioned for Critical 2025
LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a company that should be getting more attention from investors and the just released annual results again proved that point. LGVN ...